{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:04:00Z","timestamp":1761663840488},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,10]],"date-time":"2018-11-10T00:00:00Z","timestamp":1541808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jfma.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T14:46:22Z","timestamp":1542897982000},"page":"1129-1137","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response"],"prefix":"10.1016","volume":"118","author":[{"given":"Chia-Ying","family":"Chu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Tsung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hsien","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Kai","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s11894-015-0440-6","article-title":"Palliative care for patients with end-stage liver disease","volume":"17","author":"Larson","year":"2015","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jfma.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/j.gastro.2011.06.007","article-title":"Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial","volume":"141","author":"Hoefs","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.005_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gut.2003.021691","article-title":"Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study","volume":"53","author":"Ryder","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/00042737-200411000-00022","article-title":"Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis","volume":"16","author":"Abergel","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","article-title":"Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data","volume":"39","author":"Camma","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10620-014-3050-5","article-title":"All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C","volume":"59","author":"Dieperink","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jfma.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s10620-015-3773-y","article-title":"Fibrosis regression explains differences in outcome in HIV-\/HCV-coinfected patients with cirrhosis after sustained virological response","volume":"60","author":"Casado","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jfma.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1023\/A:1024196201684","article-title":"Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin","volume":"48","author":"Arif","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jfma.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2036.2008.03620.x","article-title":"Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis","volume":"27","author":"Everson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0168-8278(97)80451-5","article-title":"The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis","volume":"26","author":"Camma","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1365-2893.2003.00403.x","article-title":"Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon","volume":"10","author":"Toccaceli","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2018.11.005_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jhep.2007.07.006","article-title":"Grading and staging systems for inflammation and fibrosis in chronic liver diseases","volume":"47","author":"Goodman","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/jgh.13500","article-title":"Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: a systematic review with meta-analysis","volume":"32","author":"Liu","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.23809","article-title":"Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments","volume":"52","author":"Pockros","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jgh.14008","article-title":"Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: results from a 5-year cohort study","volume":"33","author":"Facciorusso","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib25","doi-asserted-by":"crossref","first-page":"e47715","DOI":"10.1371\/journal.pone.0047715","article-title":"Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy","volume":"7","author":"Martinez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/apt.13472","article-title":"Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C","volume":"43","author":"Lens","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"e0185609","DOI":"10.1371\/journal.pone.0185609","article-title":"Sustained virological response halts fibrosis progression: a long-term follow-up study of people with chronic hepatitis C infection","volume":"12","author":"Chen Yi Mei","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2018.11.005_bib28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0168-8278(01)00135-0","article-title":"Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis","volume":"35","author":"Grenard","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1665-2681(19)30840-3","article-title":"Long term changes in liver histology following treatment of chronic hepatitis C virus","volume":"13","author":"Shiffman","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jfma.2018.11.005_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jclinepi.2005.06.008","article-title":"Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment","volume":"59","author":"Sweeting","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jfma.2018.11.005_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/ajg.2012.137","article-title":"Reduction in hepatic inflammation is associated with less fibrosis progression and fewer clinical outcomes in advanced hepatitis C","volume":"107","author":"Morishima","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2018.11.005_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jfma.2018.11.005_bib35","first-page":"350","article-title":"Interferon alpha2b increases MMP-13 and IL-10 expression in Kupffer cells through MAPK signaling pathways","volume":"62","author":"Yu","year":"2015","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.jfma.2018.11.005_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/hep.26981","article-title":"Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis","volume":"60","author":"Roh","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2018.11.005_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/gutjnl-2013-305357","article-title":"Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters","volume":"64","author":"van der Meer","year":"2015","journal-title":"Gut"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664618304388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664618304388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T10:40:09Z","timestamp":1560508809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664618304388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0929664618304388"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2018.11.005","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}